Julia Boshuizen

Julia Boshuizen

Auto-generated profile, based on publicly available information

Julia Boshuizen

Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YSYuqiao Shen
Yuqiao Shen
FRFarah L. Rehman
Farah L. Rehman
YFYing Feng
Ying Feng
JBJulia Boshuizen
Julia Boshuizen
IBIlirjana Bajrami
Ilirjana Bajrami
AAAlan Ashworth
Alan Ashworth
Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair. Here, we describe BMN 673, a novel, highly potent PARP1/2 inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties. Experimental Design: Potency and selectivity of BMN 673 was determined by biochemical assays. Anticancer activity either as a single-agent or in combination with other antitumor agents was evaluated both in vitro and in xenograft cancer models. Results: BMN 673 is a potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L), but it does not inhibit other enzymes that we have tested. BMN 673 exhibits selective antitumor cytotoxicity and elicits DNA repair biomarkers at much lower concentrations than earlier generation PARP1/2 inhibitors (such as olaparib, rucaparib, and veliparib). In vitro, BMN 673 selectively targeted tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors. BMN 673 is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in carboxylmethyl cellulose. Oral administration of BMN 673 elicited remarkable antitumor activity in vivo; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency were profoundly sensitive to oral BMN 673 treatment at well-tolerated doses in mice. Synergistic or additive antitumor effects were also found when BMN 673 was combined with temozolomide, SN38, or platinum drugs. Conclusion: BMN 673 is currently in early-phase clinical development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class. Clin Cancer Res; 19(18); 5003–15. ©2013 AACR.

1 July 2019 in Cell
Verified
Journal Article
Closed access
DVDavid W. Vredevoogd
David W. Vredevoogd
TKThomas Kuilman
Thomas Kuilman
MLMaarten A. Ligtenberg
Maarten A. Ligtenberg
JBJulia Boshuizen
Julia Boshuizen
KSKelly E. Stecker
Kelly E. Stecker
DPDaniel S. Peeper
Daniel S. Peeper

15 January 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JBJulia Boshuizen
Julia Boshuizen
LKLouise A Koopman
Louise A Koopman
OKOscar Krijgsman
Oscar Krijgsman
ASAida Shahrabi
Aida Shahrabi
EHElke Gresnigt– van Den Heuvel
Elke Gresnigt– van Den Heuvel
PPPaul W H I Parren
Paul W H I Parren

1 June 2020 in Molecular Cell
Verified
Journal Article
Closed access
JBJulia Boshuizen
Julia Boshuizen
DPDaniel S. Peeper
Daniel S. Peeper

4 October 2017 in Nature
Verified
Journal Article
Open access
PDF file
XKXiangjun Kong
Xiangjun Kong
TKThomas Kuilman
Thomas Kuilman
ASAida Shahrabi
Aida Shahrabi
JBJulia Boshuizen
Julia Boshuizen
KKKristel Kemper
Kristel Kemper
DPDaniel S. Peeper
Daniel S. Peeper
The identification of an ERK2–JUNB–FRA1 signalling pathway that drives addiction to therapeutic drugs in cancer cells, and an ERK2-dependent phenotype switch that precedes cell death after drug withdrawal, may help to guide therapies that exploit the addiction phenotype. Cancer cells can acquire drug resistance through different genetic and non-genetic mechanisms. In some cases, drug-resistant cells become addicted to the treatment and can die upon drug withdrawal. The authors explore the mechanistic basis for this drug addiction in melanoma cells, and identify a phenotype-switch pathway that is triggered by targeted therapy. The findings suggest that alternating therapies could be tailored to exploit the drug-addiction phenotype of therapy-resistant cancer cells. Observations from cultured cells1,2,3, animal models4 and patients5,6,7 raise the possibility that the dependency of tumours on the therapeutic drugs to which they have acquired resistance represents a vulnerability with potential applications in cancer treatment. However, for this drug addiction trait to become of clinical interest, we must first define the mechanism that underlies it. We performed an unbiased CRISPR–Cas9 knockout screen on melanoma cells that were both resistant and addicted to inhibition of the serine/threonine-protein kinase BRAF, in order to functionally mine their genome for ‘addiction genes’. Here we describe a signalling pathway comprising ERK2 kinase and JUNB and FRA1 transcription factors, disruption of which allowed addicted tumour cells to survive on treatment discontinuation. This occurred in both cultured cells and mice and was irrespective of the acquired drug resistance mechanism. In melanoma and lung cancer cells, death induced by drug withdrawal was preceded by a specific ERK2-dependent phenotype switch, alongside transcriptional reprogramming reminiscent of the epithelial–mesenchymal transition. In melanoma cells, this reprogramming caused the shutdown of microphthalmia-associated transcription factor (MITF), a lineage survival oncoprotein; restoring this protein reversed phenotype switching and prevented the lethality associated with drug addiction. In patients with melanoma that had progressed during treatment with a BRAF inhibitor, treatment cessation was followed by increased expression of the receptor tyrosine kinase AXL, which is associated with the phenotype switch. Drug discontinuation synergized with the melanoma chemotherapeutic agent dacarbazine by further suppressing MITF and its prosurvival target, B-cell lymphoma 2 (BCL-2), and by inducing DNA damage in cancer cells. Our results uncover a pathway that underpins drug addiction in cancer cells, which may help to guide the use of alternating therapeutic strategies for enhanced clinical responses in drug-resistant cancers.

7 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJulia Boshuizen
Julia Boshuizen
DVDavid W. Vredevoogd
David W. Vredevoogd
OKOscar Krijgsman
Oscar Krijgsman
MLMaarten A. Ligtenberg
Maarten A. Ligtenberg
SBStephanie Blankenstein
Stephanie Blankenstein
DPDaniel S. Peeper
Daniel S. Peeper
Melanomas can switch to a dedifferentiated cell state upon exposure to cytotoxic T cells. However, it is unclear whether such tumor cells pre-exist in patients and whether they can be resensitized to immunotherapy. Here, we chronically expose (patient-derived) melanoma cell lines to differentiation antigen-specific cytotoxic T cells and observe strong enrichment of a pre-existing NGFRhi population. These fractions are refractory also to T cells recognizing non-differentiation antigens, as well as to BRAF + MEK inhibitors. NGFRhi cells induce the neurotrophic factor BDNF, which contributes to T cell resistance, as does NGFR. In melanoma patients, a tumor-intrinsic NGFR signature predicts anti-PD-1 therapy resistance, and NGFRhi tumor fractions are associated with immune exclusion. Lastly, pharmacologic NGFR inhibition restores tumor sensitivity to T cell attack in vitro and in melanoma xenografts. These findings demonstrate the existence of a stable and pre-existing NGFRhi multitherapy-refractory melanoma subpopulation, which ought to be eliminated to revert intrinsic resistance to immunotherapeutic intervention.